OmniAb, Inc.
Aaron Gerlach has extensive experience in the pharmaceutical industry, with a focus on drug discovery alliances and business development. Aaron is currently serving as the Director of Drug Discovery Alliances at OmniAb, Inc. since November 2022. Previously, they held the same role at Icagen from 2015 to 2021, where they also served as the Director of Business Development. In these positions, they led high-profile multi-site drug discovery projects and teams, and was responsible for growing the business through strategic partnerships and revenue-generating contracts. Aaron also has experience in academia, serving as a Scientific Advisory Board Member for the Pitt Hopkins Research Foundation since 2017. Before that, they worked at Pfizer as a Senior Principal Scientist from 2011 to 2015, leading pre-IND small molecule drug discovery projects and managing and training scientists. Prior to Pfizer, they held various roles at Icagen from 2003 to 2011, including Senior Research Investigator and Senior Research Scientist, where they led a successful epilepsy project and served as a member of the clinical team.
Aaron Gerlach's education history is as follows:
From 1989 to 1993, they attended Ohio University and obtained a Bachelor of Science degree in Biological Sciences.
In 1992, they completed an internship in Neuroscience at Mayo Clinic Alix School of Medicine.
Aaron then attended the University of Alabama at Birmingham from 1993 to 1995, focusing on Neuroscience.
From 1995 to 2000, they pursued a Ph.D. in Cell Biology and Physiology at the University of Pittsburgh.
Finally, from 2000 to 2003, they participated in a Postdoctoral Fellowship at Oregon Health & Science University's Vollum Institute.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.